<DOC>
	<DOCNO>NCT01632111</DOCNO>
	<brief_summary>The objective study investigate whether Agalsidase alpha , drug commonly prescribe patient Fabry disease , associate improvement pulmonary involvement . According Global Initiative Obstructive Lung Disease ( GOLD ) , surrogate marker obstructive lung disease decrease forced expiratory volume one second ( FEV1 ) FEV1/FVC ratio , whereas FVC force vital capacity . However , measurement lung function parameter indicate yearly follow-up examination without treatment Agalsidase alpha patient Fabry disease .</brief_summary>
	<brief_title>Pulmonary Involvement Patients With Fabry Disease</brief_title>
	<detailed_description>Pulmonary function test und DLCO measurement perform yearly relation yearly follow examination Department Internal Medicine University Hospital Zurich . We retrospectively collect result pulmonary function test ( spirometry ) .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Inclusion criterion : All patient establish diagnosis Fabry disease Exclusion criterion : Missing informed consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>